Abstract: The present invention relates to compounds of the formula (I): which are produced by the plant Garcinia punctata, chemical derivatives derived therefrom, a process for their preparation, and their use as pharmaceuticals, in particular for the treatment and/or prophylaxis of bacterial infectious diseases.
Type:
Grant
Filed:
July 31, 2003
Date of Patent:
October 18, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Matthias Schiell, Michael Kurz, Sabine Haag-Richter
Abstract: The present invention relates to compounds comprising the following formula: R0—Q—X—Q?—W—U—V—G—M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.
Type:
Grant
Filed:
December 21, 2001
Date of Patent:
October 11, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Marc Nazaré, David William Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
Abstract: The present invention relates to compounds of general formula (I), wherein R1-R4 have the meanings given in the specification, A is CH2, CHOH or CH—(C1-C3-alkyl), B and C are independently CH2 or CH—(C1-C3-alkyl), and R5 is an aryl or heteroaryl group optionally substituted by the substituents listed in the specification.
Abstract: Coniosulfides and their derivatives, processes for preparing them, and their use as pharmaceuticals. The present invention relates to the use of a compound of the formula (VI) for producing a pharmaceutical for the treatment and prophylaxis of degenerative neuropathics or of Alzheimer's disease.
Type:
Application
Filed:
May 18, 2005
Publication date:
September 22, 2005
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Laszlo Vertesy, Klaus Ehrlich, Marian Segeth, Luigi Toti
Abstract: Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-one systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in methods of embodiments of the invention may include compounds of the formula in which the radicals are as defined, and their physiologically acceptable salts.
Type:
Grant
Filed:
August 30, 2002
Date of Patent:
September 20, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
Abstract: The present invention relates to indazole derivatives of the general formulae I or II having the meanings indicated in the description, to the pharmaceutically useful salts thereof and the use thereof as drugs.
Type:
Application
Filed:
January 25, 2005
Publication date:
September 8, 2005
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Gerhard Zoller, Stefan Petry, Gunter Muller, Hubert Heuer, Karl-Heinz Baringhaus
Abstract: The present invention relates to indole derivatives or benzimidazole derivatives, to processes for preparing such compounds, to pharmaceutical compositions comprising such compounds, and methods for the prophylaxis and therapy of a disease associated with an increased activity of I?B kinase comprising administering such compounds.
Abstract: Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides of formula I. These compounds are found to possess the property of selectively inhibiting collagenase (MMP). They may therefore be useful in prophylaxis and therapy of diseases whose course involves an increased activity of matrix metalloproteinase 13.
Abstract: 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments The invention relates to 7-phenylamino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.
Type:
Application
Filed:
January 25, 2005
Publication date:
August 18, 2005
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Elisabeth Defossa, Dieter Kadereit, Sven Ruf, Thomas Klabunde, Dieter Schmoll, Andreas Herling, Karl-Ulrich Wendt
Abstract: Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments The invention relates to cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.
Type:
Application
Filed:
January 25, 2005
Publication date:
August 18, 2005
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Elisabeth Defossa, Dieter Kadereit, Thomas Klabunde, Dieter Schmoll, Andreas Herling, Karl-Ulrich Wendt, Sven Ruf
Abstract: The invention relates to heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.
Type:
Application
Filed:
January 25, 2005
Publication date:
August 18, 2005
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Elisabeth Defossa, Dieter Kadereit, Sven Ruf, Thomas Klabunde, Dieter Schmoll, Andreas Herling, Karl-Ulrich Wendt
Abstract: The invention describes and claims the use of vasopeptidase inhibitors of formula (I) for the treatment of nephropathy in diabetic or non-diabetic patients, including diabetic or non-diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndome, hypertensive nephrosclerosis, microalbuminuria or end stage renal disease, or insulin resistance or of metabolic diseases associated with advanced glycation end-products, such as diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, myocardial infarction and/or diabetic cardiomyopathy, or atherosclerosis or endothelial dysfunction.
Type:
Grant
Filed:
June 26, 2003
Date of Patent:
August 16, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Stefan Schäfer, Wolfgang Linz, Markus Bleich, Jochen Huber
Abstract: The present invention relates to novel active compounds named Citrullimycines, which are obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309), and to their pharmaceutically acceptable salts and derivatives. The present invention further relates to a process for the production of the Citrullimycines, to the microorganism Streptomycetes sp. ST 101396 (DSM 13309), to the use of the Citrullimycines and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, for example as inhibitors of the neurotensin receptor, and to pharmaceutical compositions comprising Citrullimycines or a pharmaceutically acceptable salt or derivative thereof.
Type:
Grant
Filed:
October 1, 2001
Date of Patent:
August 16, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Cordula Hopmann, Michael Kurz, Mark Brönstrup, Joachim Wink
Abstract: The invention relates to substituted aryl-substituted heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof, to process for their preparation and to their use as medicaments. Compounds of the Formula I in which the radicals have the stated meanings, the N-oxides thereof, and the physiologically tolerated salts thereof, and process for the preparation thereof are described. The compounds bring about for example a weight reduction in mammals and are suitable for example for the prevention and treatment of obesity and diabetes.
Type:
Application
Filed:
January 25, 2005
Publication date:
August 11, 2005
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Lothar Schwink, Siegfried Stengelin, Thomas Boehme, Matthias Gossel, Gerhard Hessler, Petra Stahl
Abstract: The present invention relates to LIMK-1, a LIMK-1-analogue or LIMK-1 ligand for the binding to GPIIb and/or activation or inhibition of GPIIb/IIIa downstream signaling, for the production of a medicament for the prevention or treatment of a thrombus formation or blood clotting disease, methods of screening a LIMK-1 analogue or a LIMK-1 ligand and a method for producing a medicament for the treatment of a thrombus formation or blood clotting disease.
Type:
Application
Filed:
November 17, 2004
Publication date:
August 11, 2005
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Alexander Rueck, Thomas Leeuw, Matthias Herrmann, Gertrud Sibenhorn
Abstract: The present invention relates to compounds of the formula which are formed during fermentation by the microorganism Coniochaeta ellipsoidea Udagawa, DSM 13856, or by one of its mutations and/or variants, and chemically derivatized if appropriate. The invention furthermore relates to a process for preparing compounds of the formula (I), and to their use as pharmaceuticals. In addition, the invention relates to the use of a compound of the formula (VI) for producing a pharmaceutical for the treatment and prophylaxis of degenerative neuropathics or of Alzheimer's disease.
Type:
Grant
Filed:
September 19, 2002
Date of Patent:
August 9, 2005
Assignee:
Aventis Pharma Deutschland GmbH.
Inventors:
Laszlo Vertesy, Klaus Ehrlich, Michael Kurz, Marian Paul Segeth, Luigi Toti
Abstract: The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
Type:
Grant
Filed:
December 13, 1994
Date of Patent:
August 9, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Klaus Bosslet, Gerhard Seemann, Hans Harald Sedlacek, Bernhard Auerbach